Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 5/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162968 | 0.71 | ALDH1A1 (0.36) | ALDH1A1TSHRNOS1HSD17B10FBP1 | |
| SCHEMBL17701189 | 0.68 | DGAT1 (0.45) | LPLLIPG | |
| SCHEMBL29514317 | 0.67 | LPL (0.35) | LPLLIPGP2RX7 | |
| SCHEMBL25199762 | 0.67 | NOS1 (0.38) | LPLLIPGNOS1P2RX7MAPK1 | |
| SCHEMBL28736684 | 0.67 | SMN1; SMN2 (0.38) | LPLLIPGNOS1P2RX7MAPK1 | |
| SCHEMBL13274897 | 0.67 | LIPG (0.47) | LPLLIPG | |
| SCHEMBL1535070 | 0.66 | LPL (0.41) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL1851608 | 0.64 | LPL (0.41) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL793512 | 0.64 | LPL (0.41) | LPLLIPGP2RX7MAPK1 | |
| SCHEMBL17196072 | 0.63 | LPL (0.33) | LPLLIPGALDH1A1P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559310-B2 | Reacting a halogen aromatic derivative at a coupling position with a diboron derivative in the presence of a Group VIII metal catalyst and a suitable base for covalently coupling organic compounds | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2003-05-06 | — | — | US | claimed |
| US-20020193604-A1 | Aryl borates | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2002-12-19 | — | — | US | claimed |
| EP-0986541-A4 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMW SCIENT IND RES ORG (AU) | 2002-08-14 | — | — | EP | claimed |
| US-20020032339-A1 | ARYL BORATES | BORON MOLECULAR LIMITED (AU) | 2002-03-14 | — | — | US | claimed |
| EP-0986541-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-03-22 | — | — | EP | claimed |
| WO-1998045265-A1 | PROCESS FOR COVALENTLY COUPLING ORGANIC COMPOUNDS UTILIZING DIBORON DERIVATIVES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 1998-10-15 | — | — | WO | claimed |
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| WO-2024243502-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4396191-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2024-07-10 | — | — | EP | disclosed |
| WO-2023033740-A9 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2023-12-28 | — | — | WO | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | SANOFI (FR) | 2014-10-02 | — | — | US | disclosed |
| WO-2014144737-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| CN-100491323-C | Biaryloxymethylarenecarboxylic acids compound | HOFFMANN LA ROCHE (CH) | 2009-05-27 | — | — | CN | disclosed |
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| CN-1812956-A | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN LA ROCHE (CH) | 2006-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296233-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | LPL 591/4885LIPG 807/4885ALDH1A1 684/4885 |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | LPL 2169/4885LIPG 3446/4885ALDH1A1 2764/4885 |
| US-20020193604-A1 | Aryl borates | BRD4, ABL1, BRD3 | LPL 4181/4885LIPG 4621/4885ALDH1A1 1148/4885 |
| US-20020032339-A1 | ARYL BORATES | TBCB, HAT1, UBE2B | LPL 4584/4885LIPG 4847/4885ALDH1A1 968/4885 |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | LPL 1979/4885LIPG 1027/4885ALDH1A1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.